Pharming Novartis announces first commercial shipments of Joenja in U.S.

Pharming (PHAR) announced the first commercial shipments of Joenja to patients in the United States. Joenja, an oral, selective PI3Kdelta inhibitor, is the first and only treatment approved in the U.S. for activated phosphoinositide 3-kinase delta syndrome, or APDS, a rare and progressive primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Under the terms of Pharming’s 2019 exclusive license agreement with Novartis (NVS) for leniolisib, the corresponding first commercial sale of Joenja triggers a $10M milestone payment by Pharming to Novartis.